Last reviewed · How we verify
NCT04869631: SAVER
Screening for Amyloidosis Before Aortic Valve Elective Replacement
trial testing The outcome of an intervention is not evaluated, but aortic stenosis and additional amyloidosis are compared. in Amyloidosis in 1,000 participants. Participants enrolled and being followed up; not accepting new ones.
31 March 2023
Quick facts
| Lead sponsor | Charite University, Berlin, Germany |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 1 February 2021 |
| Primary completion | 31 March 2023 |
| Estimated completion | 31 March 2028 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- The outcome of an intervention is not evaluated, but aortic stenosis and additional amyloidosis are compared.
Conditions studied
- Amyloidosis — all drugs for Amyloidosis →
- Aortic Valve Stenosis — all drugs for Aortic Valve Stenosis →
Sponsor
Charite University, Berlin, Germany
Who can join
Adults 40 to 99, any sex, with Amyloidosis or Aortic Valve Stenosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Previous studies detected that up to 15% of patients undergoing aortic valve replacement (AVR) for degenerative aortic stenosis have concomitant transthyretin amyloidosis (ATTR) cardiomyopathy (Castano, 2017). The aim of this study is to investigate the effectivity and practicability of a systematic ATTR-Screening in patients undergoing planned AVR. Moreover, we plan to develop a screening algorithm to detect ATTR in aortic stenosis (AS).
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Evaluation of the cardiac amyloidosis clinical pathway implementation: a real-world experience.
Brons M, Muller SA, Rutten FH, van der Meer MG, et al · · 2022 · cited 24× · PMID 35919127 · DOI 10.1093/ehjopen/oeac011 -
Suspicion, screening, and diagnosis of wild-type transthyretin amyloid cardiomyopathy: a systematic literature review.
Bay K, Gustafsson F, Maiborg M, Bagger-Bahnsen A, et al · · 2022 · cited 16× · PMID 35343098 · DOI 10.1002/ehf2.13884
Verify or expand the search:
- PubMed search for NCT04869631
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Amyloidosis
Currently open trials in the same condition.
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT06974877 — Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure · Phase 1 · recruiting
- NCT07081646 — A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloido · Phase 1, PHASE2 · recruiting
- NCT07232459 — [18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis · recruiting
- NCT06573723 — Institutional Registry of Rare Diseases · recruiting
Other Charite University, Berlin, Germany trials
Trials by the same sponsor.
- NCT07486167 — Influence of Lung Volume Optimization Maneuver on Cardiac Output and Lung Compliance in Ventilated Children With Congeni · Phase 1, PHASE2 · not yet recruiting
- NCT07476729 — International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) · Phase 3 · not yet recruiting
- NCT07503054 — Ovarian Cancer Screening and AI · NA · not yet recruiting
- NCT07529197 — Observational Study on Immunoadsorption (IA) in Patients With Autoantibody-Positive Post-Infectious ME/CFS · recruiting
- NCT07388693 — Feasibility of Integrating Olfactory Stimuli Into Virtual Reality Cue Exposure for Patients With Alcohol Dependence · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04869631 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Charite University, Berlin, Germany
- Last refreshed: 12 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04869631.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing